Agenus Inc. (AGEN)
NASDAQ: AGEN
· Real-Time Price · USD
6.07
0.56 (10.16%)
At close: Jul 03, 2025, 3:54 PM
10.16% (1D)
| Bid | 5.99 |
| Market Cap | 166.42M |
| Revenue (ttm) | 99.52M |
| Net Income (ttm) | -190.65M |
| EPS (ttm) | 29.61 |
| PE Ratio (ttm) | 0.2 |
| Forward PE | 5.46 |
| Analyst | Hold |
| Ask | 6.09 |
| Volume | 1,273,135 |
| Avg. Volume (20D) | 1,133,980 |
| Open | 5.51 |
| Previous Close | 5.51 |
| Day's Range | 5.48 - 6.20 |
| 52-Week Range | 1.38 - 18.74 |
| Beta | 1.43 |
About AGEN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AGEN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AGEN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Agenus Inc. is scheduled to release its earnings on Aug 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+12.6%
Agenus shares are trading higher after HC Wainwrig...
Unlock content with
Pro Subscription
1 month ago
+21.07%
Agenus shares are trading higher after the company announced it signed a partnership agreement with Zydus Lifesciences to expand patient access to Botensilimab and Balstilimab.
